ABG
BDTX icon

Ally Bridge Group’s Black Diamond Therapeutics BDTX Stock Holding History

Ally Bridge Group’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-835,000
Closed -$3.89M – 31
2024
Q2 		$3.89M Buy
+835,000
New +$4.48M 2.32% 22
2023
Q4 		– Sell
-634,191
Closed -$1.82M – 24
2023
Q3 		$1.82M Sell
634,191
-165,809
-21% -$611K 2.14% 14
2023
Q2 		$4.04M Buy
+800,000
New +$1.63M 4.89% 10

Other funds holding BDTX

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return

Ally Bridge Group's BDTX Position: Q3 2024 in Review

Ally Bridge Group sold out of Black Diamond Therapeutics (BDTX) in Q3 2024, closing a stake of 835,000 shares — an estimated $3.89M sold.

Ally Bridge Group first reported a position in BDTX in Q2 2023 and held it in 3 quarters. The position peaked at $4.04M in Q2 2023. 96 funds tracked by Wall St. Rank hold BDTX as of Q3 2024.

  • Ally Bridge Group reported no remaining Black Diamond Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Ally Bridge Group sold 835,000 Black Diamond Therapeutics shares in Q3 2024, an estimated $3.89M.
  • Ally Bridge Group first reported a position in Black Diamond Therapeutics in Q2 2023 and held it in 3 quarters.
  • Ally Bridge Group's Black Diamond Therapeutics position peaked at $4.04M in Q2 2023.
  • 96 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q3 2024.

Based on Ally Bridge Group's 13F filing for Q3 2024, filed 14 Nov 2024.